Pharmacy Gag Clause Ban Vote Tops SPT Week in Review

Top news of the week from Specialty Pharmacy Times.

5. FDA OKs Preventive Treatment for Migraines

Officials with the FDA have approved fremanezumab-vfrm (Ajovy, Teva) for the preventive treatment of migraine in adults. Read more.

4. New Plaque Psoriasis Treatment Approved in Europe

Tildrakizumab (Ilumetri) received approval by the European Commission for the treatment of moderate-to-severe chronic plaque psoriasis. Read more.

3. FDA: No Unexpected Safety Risks Associated With Pimavanserin

The FDA did not identify any new or unexpected safety findings with pimavanserin (Nuplazid), nor findings that are inconsistent with the established safety profile currently described in the drug label. Read more.

2. NCCN Recommends Cabozantinib for Advanced RCC Treatment Across All Patient Risk Groups

The National Comprehensive Cancer Network updated its Clinical Practice Guidelines for kidney cancer to include new recommendations for cabozantinib tablets. Read more.

1. Senate Passes Bill to Prohibit Pharmacy Gag Clauses

The Patient Right to Know Drug Prices Act would prohibit insurers and prescription benefit managers from using gag clauses by health insurers and pharmacy benefit managers. Read more.